[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356306-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356306-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","camizestrant-in-combination-with-capivasertib-for-women-with-er-positive-her2-negative-advanced-breast-cancer-results-from-serena-1","Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1","","Camizestrant, an oral selective estrogen receptor degrader (SERD) and complete estrogen receptor antagonist, previously showed superiority to fulvestrant in ER-positive, HER2-negative advanced breast cancer. Capivasertib, a selective AKT inhibitor, is recommended with fulvestrant for patients with PIK3CA/AKT1/PTEN-altered disease. SERENA-1 Parts I and J assess safety, tolerability, pharmacokinetics, and efficacy of camizestrant 75 mg with capivasertib 400 mg in phase I, open-label, multi-part trial cohorts. Among 29 participants, diarrhea and nausea were most common; clinical benefit at 24 weeks was 51.7%, with median progression-free survival of 8.3 months.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/camizestrant-in-combination-with-capivasertib-for-women-with-er-positive-her2-negative-advanced-breast-cancer-results-from-serena-1/356306/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/camizestrant-in-combination-with-capivasertib-for-women-with-er-positive-her2-negative-advanced-breast-cancer-results-from-serena-1/356306.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",17,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is camizestrant and why was it studied in this trial?","Question",{"text":63,"@type":64},"Camizestrant is a next-generation oral SERD and complete estrogen receptor antagonist. It was studied because it previously demonstrated superiority over fulvestrant in ER-positive, HER2-negative advanced breast cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does capivasertib fit into treatment, and what was the tested combination?",{"text":68,"@type":64},"Capivasertib is a selective AKT inhibitor recommended with fulvestrant for PIK3CA/AKT1/PTEN-altered ER-positive, HER2-negative advanced breast cancer. SERENA-1 tested camizestrant 75 mg once daily combined with capivasertib 400 mg (4 days on, 3 days off).",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key safety and efficacy outcomes reported?",{"text":72,"@type":64},"The combination showed a well-tolerated safety profile, with diarrhea (75.9%) and nausea (44.8%) as the most common adverse events. Clinical benefit at 24 weeks was 51.7%, and median progression-free survival was 8.3 months.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356306,1790167469,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","ORIGINAL ARTICLE  \nCamizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1✫  \nC. Vaklavas1, M. Oliveira2, A. C. Armstrong3, I. Moreno4, C. Twelves5, I. Victoria Ruiz6, B. Bermejo de las Heras7, T. Brier8, C. Ciardullo8, L. Gibbons8, T. Jack8, T. Klinowska9, J. P. O. Lindemann8, A. M. Mathewson8, R. Maudsley8, C. J. Morrow8,  \nA. Sykes10 & R. D. Baird11 ∗  \n1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; 2Medical Oncology Department, Vall d’Hebron University Hospital and Breast Cancer Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain; 3The Christie NHS Foundation Trust and the University of Manchester, Manchester, UK; 4START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain; 5University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK; 6Department of Medical Oncology, IDIBAPS, Hospital Clínic, Barcelona; 7Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain; 8Research and Early Development, Oncology R&D, AstraZeneca, Cambridge; 9Late Development, Oncology R&D, AstraZeneca, Cambridge; 10Clinical Pharmacology and Safety Sciences, Biopharmaceutical Sciences, AstraZeneca, Cambridge; 11Cancer Research UK, Cambridge Centre, Cambridge, UK  \nAvailable online xxx  \nBackground: Camizestrant, the next-generation oral selective estrogen receptor degrader and complete estrogen receptor (ER) antagonist, has previously demonstrated superiority over fulvestrant in patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Capivasertib is a selective AKT inhibitor recommended with fulvestrant for patients with PIK3CA/AKT1/PTEN-altered ER-positive, HER2-negative advanced breast cancer. Here, we report data from Parts I and J of SERENA-1 (NCT03616587), evaluating the safety, tolerability, pharmacokinetics and efficacy for the combination of camizestrant and capivasertib.  \nPatients and methods: SERENA-1 is a phase I, open-label, multi-part trial of camizestrant alone and in combination with other anticancer agents in women with ER-positive, HER2-negative advanced breast cancer. In parts I and J, participants received oral camizestrant 75 mg (once daily) in combination with oral capivasertib 400 mg (4 days on, 3 days off) . Results: Participants (n = 29) had a median of two previous lines of therapy in the advanced setting; 55. 2% had received fulvestrant and 89.7% had received a cyclin-dependent kinase 4/6 inhibitor. Camizestrant in combination with capivasertib had a well-tolerated safety profile, with diarrhea (75 .9%) and nausea (44 .8%) being the most common adverse events. Median tmax was achieved ∼4 hours and ∼2 hours post dose for camizestrant and capivasertib, respectively. Clinical benefit at 24 weeks was seen in 51.7% of participants, and median progressionfree survival was 8.3 months.  \nConclusion: In these pretreated participants, camizestrant 75 mg in combination with capivasertib 400 mg was well tolerated, with a side effect profile consistent with each drug as monotherapy, and showed encouraging evidence of clinical efficacy.  \nKey words: breast cancer, endocrine therapy, estrogen receptor, hormone receptor, clinical trial, SERD  \nINTRODUCTION  \nBreast cancer remains the second most common cancer globally and the leading cause of cancer death in women. Despite recent advances in the management of breast cancer, there remains a major unmet need to improve outcomes for patients.1,2  \n*Correspondence to: Dr Richard D. Baird, Precision Breast Cancer Institute, Cancer Research UK Cambridge Centre, Addenbrooke’s Hospital Box 97, Hills Road, Cambridge, UK, CB2 0RE. Tel: +44-1223-367045  \nE-mail: [rdb39@cam.ac.uk](rdb39@cam.ac.uk) (R. D. Baird).  \n✫Note: This study was previously presented at the San Antonio Breast Cancer Symposium (SABCS) 2023.  \n2059-7029/© 2025 The Author(s). Published by Elsevier Ltd on behal","cbCaicTQlIe1qWiA","https://ap.wps.com/l/cbCaicTQlIe1qWiA","pdf",770845,11,"English","# Background\n# Patients and methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is camizestrant and why was it studied in this trial?\",\"answer\":\"Camizestrant is a next-generation oral SERD and complete estrogen receptor antagonist. It was studied because it previously demonstrated superiority over fulvestrant in ER-positive, HER2-negative advanced breast cancer.\"},{\"question\":\"How does capivasertib fit into treatment, and what was the tested combination?\",\"answer\":\"Capivasertib is a selective AKT inhibitor recommended with fulvestrant for PIK3CA/AKT1/PTEN-altered ER-positive, HER2-negative advanced breast cancer. SERENA-1 tested camizestrant 75 mg once daily combined with capivasertib 400 mg (4 days on, 3 days off).\"},{\"question\":\"What were the key safety and efficacy outcomes reported?\",\"answer\":\"The combination showed a well-tolerated safety profile, with diarrhea (75.9%) and nausea (44.8%) as the most common adverse events. Clinical benefit at 24 weeks was 51.7%, and median progression-free survival was 8.3 months.\"}]","Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1 | PDF",1790124539,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/81ac300608a528103ad2701948f1565d.webp",983,1269,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c0e200ea37ce8e79aceee0e58ac34be8.webp",982,1268,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/366d36d8b11efee18d03449eef49d1ba.webp",981,1266,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a93fb5240985b43f7db8acc0cfba2e02.webp",980,1265]